Posts
November 13 2023
Xortx Therapeutics, Inc. announced the commencement of its At the Market offering in the amount of $3,700,000. EG&S acted as counsel to the Manager.
November 13 2023
MAIA Biotechnology, Inc. announced the closing of its Registered Direct offering in the amount of $4,000,000. EG&S acted as counsel to the Placement Agent.
November 06 2023
PaxMedica, Inc. announced the closing of its Public Offering in the amount of $7,000,000. EG&S acted as counsel to the Placement Agent.
November 05 2023
Dolphin Entertainment, Inc. announced the closing of its Public Offering of Common Stock in the amount of $2,310,000. EG&S acted as counsel to the Underwriter.
November 03 2023
Bitfarms Ltd. announced the closing of its Private Placement with U.S Institutional Investors in the amount of CAD$60,000,000. EG&S acted as counsel to the Placement Agent.
November 02 2023
BioCardia, Inc. announced the closing of its Registered Direct offering in the amount of $1,300,000. EG&S acted as counsel to the Placement Agent.
October 31 2023
Vivos Therapeutics, Inc., a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced the pricing of its private placement in the amount of $4,000,000. EGS acted as counsel to Vivos Therapeutics, Inc.
October 31 2023
Dolphin Entertainment, a leader in entertainment marketing, announced the pricing of its previously announced underwritten public offering in the amount of $2,300,000. EGS acted as counsel to Maxim Group LLC, the sole book-running manager for the Offering.